Derivatives of oxazaphosphorines and therapeutic uses thereof

US10098901B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10098901-B2
Application numberUS-201515310455-A
CountryUS
Kind codeB2
Filing dateMay 13, 2015
Priority dateMay 14, 2014
Publication dateOct 16, 2018
Grant dateOct 16, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to novel derivatives of oxazaphosphorines, pharmaceutical compositions and therapeutic uses thereof, in particular for treating or preventing cancer.

First claim

Opening claim text (preview).

The invention claimed is: 1. A compound of formula (I): wherein: A is selected from the group consisting of: O, S, —O—(C═S)—S—, —ONH—, —ONR′—, —NR′O—, —NHO—, Y 1 —(CH 2 ) n —Y 2 , where n is an integer from 1 to 8, and Y 1 —(CH 2 —CH 2 —O) a —CH 2 —CH 2 —Y 2 where a is an integer from 1 to 5, wherein Y 1 and Y 2 are independently selected from —O—, —NH—, —S—, —OC(O)—, —C(O)NH—, —NHC(O)—, —O—C(S)—S—, S—C(S)—O—NR′—, —ONH—, —NHO—, —ONR′—, —NR′O—, —OC(O)—O—, NR′C(S)S—, —SC(S)NR′—, —NR′C(O)—, —C(O)NR′— and —C(O)O—, and R′ is a C 1 -C 6 alkyl, and wherein —R 1 , R 2 and R 3 are independently selected from the group consisting of —H, —CH(CH 3 )—CH 2 —X and —(CH 2 ) 2 —X, X being a halogen atom, or a pharmaceutically acceptable salt or solvate thereof. 2. A compound selected from the group consisting of: and pharmaceutically acceptable salts thereof. 3. A pharmaceutical composition comprising a compound as an active ingredient and a pharmaceutically acceptable excipient, wherein the compound is:

Assignees

Inventors

Classifications

  • Antineoplastic agents · CPC title

  • the modifying agent being an organic compound · CPC title

  • A61K31/664Primary

    Amides of phosphorus acids · CPC title

  • Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids (hydroxamic acids A61K31/16; peroxy acids A61K31/327) · CPC title

  • the phosphorus atom being part of a six-membered ring which may be condensed with another ring system · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10098901B2 cover?
The present invention relates to novel derivatives of oxazaphosphorines, pharmaceutical compositions and therapeutic uses thereof, in particular for treating or preventing cancer.
Who is the assignee on this patent?
Roussy Inst Gustave
What technology area does this patent fall under?
Primary CPC classification A61K31/664. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Oct 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).